Kraft Heinz confirms plans to split into two public companies by second half 2026
WASHINGTON - Danaher Corporation (NYSE:DHR), a $144.5 billion market cap company and prominent player in the Life Sciences Tools & Services industry according to InvestingPro, has appointed Greg Milosevich as Executive Vice President with responsibility for its Life Sciences business, effective July 1, 2025, according to a company press release.
Milosevich, who has served as Vice President and Group Executive of the Life Sciences Innovations Group since 2021, will become an executive officer of Danaher while continuing to report to President and CEO Rainer Blair. The company maintains strong financial health with a "GOOD" overall rating from InvestingPro, supported by robust cash flows and moderate debt levels.
In his current role, Milosevich oversees multiple Danaher companies including Beckman Coulter Life Sciences, Sciex, Leica Microsystems, Molecular Devices, Phenomenex, Abcam, IDBS and Genedata.
Milosevich joined Danaher in 2010 through the acquisition of Molecular Devices and has held positions of increasing responsibility across multiple businesses within the company. He holds a bachelor’s degree in physics from the University of Puget Sound.
"Greg has played a pivotal role in advancing our Life Sciences Innovations Group over the past four years," said Blair in the statement.
Danaher, which describes itself as a global life sciences and diagnostics innovator, employs approximately 63,000 people worldwide. The company focuses on technologies that enable faster and more accurate diagnoses while reducing time and costs associated with therapy development. With annual revenue of $23.8 billion and a strong gross profit margin of 59.8%, analysts maintain a bullish outlook on the stock with a consensus "Strong Buy" recommendation. Discover more detailed insights and 12 additional ProTips about Danaher in the comprehensive Pro Research Report, available exclusively on InvestingPro.
The appointment comes as Danaher continues to position its leadership team to advance its presence in the life sciences sector, which represents a significant portion of the company’s business portfolio.
In other recent news, Danaher Corporation has announced a strategic partnership with AstraZeneca to develop advanced AI-powered diagnostic tests aimed at enhancing precision medicine. This collaboration will focus on creating digital and computational pathology products to improve patient diagnosis and selection for precision medicine therapies. Concurrently, Danaher shareholders have approved the executive compensation and the selection of Ernst & Young LLP as the independent public accounting firm for the fiscal year ending December 31, 2025. The voting results, which were filed with the SEC, indicated strong shareholder support for these measures.
Analysts have also been active in evaluating Danaher’s stock. Stifel has maintained a Buy rating with a price target of $260, citing robust financial performance and management’s optimistic outlook. Similarly, TD Cowen has raised its price target to $248, highlighting a recovery in the bioprocess sector and a reduction in EPS risk. Barclays analyst Luke Sergott increased the price target to $215, noting Danaher’s effective strategies to mitigate tariff impacts and its favorable positioning in stable demand markets. These developments reflect a positive sentiment among analysts regarding Danaher’s strategic direction and operational resilience.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.